utah778/iStock via Getty Images Update 6:20pm: Adds new United Therapeutics lawsuit against Liquidia. Liquidia ( NASDAQ: LQDA ) jumped 12% in after hours trading after a judge denied United Therapeutics request for a preliminary injunction over lung-disease drug Yutrepia. "Although Plaintiff has shown a likelihood of success as to infringement of claims 1, 6, 9, and 10 of the '327 patent," Plaintiff has failed to show the Defendants's obviousness challenge lacks substantial merit," US District Judge Richard G.
Andrews wrote in an opinion on Friday. "Plaintiff has also failed to show that it is likely to suffer irreparable harm absent an injunction, or that the public interest weighs in favor of an injunction." Liquidia ( LQDA ) had a court win in its patent dispute with United Therapeutics from Judge Andrews in late March.
Liquidia ( LQDA ) soared 36% on Dec. 20 after a court victory in its patent dispute with UTHR. United Therapeutics ( NASDAQ: UTHR ) attempt for a preliminary injunction to stop the Food & Drug Administration from approving Liquidia's ( LQDA ) Yutrepia lung-disease drug was also denied by a judge in late March.
U.S. District Judge John D.
Bates denied United Therapeutics ( UTHR ) request for a preliminary injunction and a temporary restraining order. United Therapeutics ( UTHR ) markets its version of treprostinil as Tyvaso, and the FDA granted tentative approval for a generic to Liquidia ( LQDA ) in 2021, allowing for its potential market entry as Yutrepia .
